Medical Care
Global Thrombopoiesis Stimulating Agents Market Research Report 2025
- May 12, 25
- ID: 234248
- Pages: 85
- Figures: 86
- Views: 7
The global market for Thrombopoiesis Stimulating Agents was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Thrombopoiesis Stimulating Agents is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Thrombopoiesis Stimulating Agents is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Thrombopoiesis Stimulating Agents in Adults is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Thrombopoiesis Stimulating Agents include Amgen, Kyowa Kirin, Intas Pharmaceuticals, SHIONOGI, Novartis Pharma, AkaRx, Rigel Pharmaceuticals, Kissei Pharmaceutical, Grifols, JW Pharmaceutical Corporation, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Thrombopoiesis Stimulating Agents, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Thrombopoiesis Stimulating Agents.
The Thrombopoiesis Stimulating Agents market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Thrombopoiesis Stimulating Agents market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Thrombopoiesis Stimulating Agents companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Kyowa Kirin
Intas Pharmaceuticals
SHIONOGI
Novartis Pharma
AkaRx
Rigel Pharmaceuticals
Kissei Pharmaceutical
Grifols
JW Pharmaceutical Corporation
Medison Pharma Canada
AstraZeneca
Segment by Type
Romiplostim
Fostamatinib
Mulpleta
Doptelet
Others
Segment by Application
Adults
Pediatric Patients
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Thrombopoiesis Stimulating Agents company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for Thrombopoiesis Stimulating Agents is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Thrombopoiesis Stimulating Agents is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Thrombopoiesis Stimulating Agents in Adults is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Thrombopoiesis Stimulating Agents include Amgen, Kyowa Kirin, Intas Pharmaceuticals, SHIONOGI, Novartis Pharma, AkaRx, Rigel Pharmaceuticals, Kissei Pharmaceutical, Grifols, JW Pharmaceutical Corporation, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Thrombopoiesis Stimulating Agents, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Thrombopoiesis Stimulating Agents.
The Thrombopoiesis Stimulating Agents market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Thrombopoiesis Stimulating Agents market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Thrombopoiesis Stimulating Agents companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Kyowa Kirin
Intas Pharmaceuticals
SHIONOGI
Novartis Pharma
AkaRx
Rigel Pharmaceuticals
Kissei Pharmaceutical
Grifols
JW Pharmaceutical Corporation
Medison Pharma Canada
AstraZeneca
Segment by Type
Romiplostim
Fostamatinib
Mulpleta
Doptelet
Others
Segment by Application
Adults
Pediatric Patients
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Thrombopoiesis Stimulating Agents company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Thrombopoiesis Stimulating Agents Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Romiplostim
1.2.3 Fostamatinib
1.2.4 Mulpleta
1.2.5 Doptelet
1.2.6 Others
1.3 Market by Application
1.3.1 Global Thrombopoiesis Stimulating Agents Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Adults
1.3.3 Pediatric Patients
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Thrombopoiesis Stimulating Agents Market Perspective (2020-2031)
2.2 Global Thrombopoiesis Stimulating Agents Growth Trends by Region
2.2.1 Global Thrombopoiesis Stimulating Agents Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Thrombopoiesis Stimulating Agents Historic Market Size by Region (2020-2025)
2.2.3 Thrombopoiesis Stimulating Agents Forecasted Market Size by Region (2026-2031)
2.3 Thrombopoiesis Stimulating Agents Market Dynamics
2.3.1 Thrombopoiesis Stimulating Agents Industry Trends
2.3.2 Thrombopoiesis Stimulating Agents Market Drivers
2.3.3 Thrombopoiesis Stimulating Agents Market Challenges
2.3.4 Thrombopoiesis Stimulating Agents Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Thrombopoiesis Stimulating Agents Players by Revenue
3.1.1 Global Top Thrombopoiesis Stimulating Agents Players by Revenue (2020-2025)
3.1.2 Global Thrombopoiesis Stimulating Agents Revenue Market Share by Players (2020-2025)
3.2 Global Thrombopoiesis Stimulating Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Thrombopoiesis Stimulating Agents Revenue
3.4 Global Thrombopoiesis Stimulating Agents Market Concentration Ratio
3.4.1 Global Thrombopoiesis Stimulating Agents Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Thrombopoiesis Stimulating Agents Revenue in 2024
3.5 Global Key Players of Thrombopoiesis Stimulating Agents Head office and Area Served
3.6 Global Key Players of Thrombopoiesis Stimulating Agents, Product and Application
3.7 Global Key Players of Thrombopoiesis Stimulating Agents, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Thrombopoiesis Stimulating Agents Breakdown Data by Type
4.1 Global Thrombopoiesis Stimulating Agents Historic Market Size by Type (2020-2025)
4.2 Global Thrombopoiesis Stimulating Agents Forecasted Market Size by Type (2026-2031)
5 Thrombopoiesis Stimulating Agents Breakdown Data by Application
5.1 Global Thrombopoiesis Stimulating Agents Historic Market Size by Application (2020-2025)
5.2 Global Thrombopoiesis Stimulating Agents Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Thrombopoiesis Stimulating Agents Market Size (2020-2031)
6.2 North America Thrombopoiesis Stimulating Agents Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025)
6.4 North America Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Thrombopoiesis Stimulating Agents Market Size (2020-2031)
7.2 Europe Thrombopoiesis Stimulating Agents Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025)
7.4 Europe Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Thrombopoiesis Stimulating Agents Market Size (2020-2031)
8.2 Asia-Pacific Thrombopoiesis Stimulating Agents Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Thrombopoiesis Stimulating Agents Market Size by Region (2020-2025)
8.4 Asia-Pacific Thrombopoiesis Stimulating Agents Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Thrombopoiesis Stimulating Agents Market Size (2020-2031)
9.2 Latin America Thrombopoiesis Stimulating Agents Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025)
9.4 Latin America Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Thrombopoiesis Stimulating Agents Market Size (2020-2031)
10.2 Middle East & Africa Thrombopoiesis Stimulating Agents Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025)
10.4 Middle East & Africa Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Thrombopoiesis Stimulating Agents Introduction
11.1.4 Amgen Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.1.5 Amgen Recent Development
11.2 Kyowa Kirin
11.2.1 Kyowa Kirin Company Details
11.2.2 Kyowa Kirin Business Overview
11.2.3 Kyowa Kirin Thrombopoiesis Stimulating Agents Introduction
11.2.4 Kyowa Kirin Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.2.5 Kyowa Kirin Recent Development
11.3 Intas Pharmaceuticals
11.3.1 Intas Pharmaceuticals Company Details
11.3.2 Intas Pharmaceuticals Business Overview
11.3.3 Intas Pharmaceuticals Thrombopoiesis Stimulating Agents Introduction
11.3.4 Intas Pharmaceuticals Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.3.5 Intas Pharmaceuticals Recent Development
11.4 SHIONOGI
11.4.1 SHIONOGI Company Details
11.4.2 SHIONOGI Business Overview
11.4.3 SHIONOGI Thrombopoiesis Stimulating Agents Introduction
11.4.4 SHIONOGI Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.4.5 SHIONOGI Recent Development
11.5 Novartis Pharma
11.5.1 Novartis Pharma Company Details
11.5.2 Novartis Pharma Business Overview
11.5.3 Novartis Pharma Thrombopoiesis Stimulating Agents Introduction
11.5.4 Novartis Pharma Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.5.5 Novartis Pharma Recent Development
11.6 AkaRx
11.6.1 AkaRx Company Details
11.6.2 AkaRx Business Overview
11.6.3 AkaRx Thrombopoiesis Stimulating Agents Introduction
11.6.4 AkaRx Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.6.5 AkaRx Recent Development
11.7 Rigel Pharmaceuticals
11.7.1 Rigel Pharmaceuticals Company Details
11.7.2 Rigel Pharmaceuticals Business Overview
11.7.3 Rigel Pharmaceuticals Thrombopoiesis Stimulating Agents Introduction
11.7.4 Rigel Pharmaceuticals Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.7.5 Rigel Pharmaceuticals Recent Development
11.8 Kissei Pharmaceutical
11.8.1 Kissei Pharmaceutical Company Details
11.8.2 Kissei Pharmaceutical Business Overview
11.8.3 Kissei Pharmaceutical Thrombopoiesis Stimulating Agents Introduction
11.8.4 Kissei Pharmaceutical Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.8.5 Kissei Pharmaceutical Recent Development
11.9 Grifols
11.9.1 Grifols Company Details
11.9.2 Grifols Business Overview
11.9.3 Grifols Thrombopoiesis Stimulating Agents Introduction
11.9.4 Grifols Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.9.5 Grifols Recent Development
11.10 JW Pharmaceutical Corporation
11.10.1 JW Pharmaceutical Corporation Company Details
11.10.2 JW Pharmaceutical Corporation Business Overview
11.10.3 JW Pharmaceutical Corporation Thrombopoiesis Stimulating Agents Introduction
11.10.4 JW Pharmaceutical Corporation Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.10.5 JW Pharmaceutical Corporation Recent Development
11.11 Medison Pharma Canada
11.11.1 Medison Pharma Canada Company Details
11.11.2 Medison Pharma Canada Business Overview
11.11.3 Medison Pharma Canada Thrombopoiesis Stimulating Agents Introduction
11.11.4 Medison Pharma Canada Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.11.5 Medison Pharma Canada Recent Development
11.12 AstraZeneca
11.12.1 AstraZeneca Company Details
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Thrombopoiesis Stimulating Agents Introduction
11.12.4 AstraZeneca Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.12.5 AstraZeneca Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Thrombopoiesis Stimulating Agents Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Romiplostim
1.2.3 Fostamatinib
1.2.4 Mulpleta
1.2.5 Doptelet
1.2.6 Others
1.3 Market by Application
1.3.1 Global Thrombopoiesis Stimulating Agents Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Adults
1.3.3 Pediatric Patients
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Thrombopoiesis Stimulating Agents Market Perspective (2020-2031)
2.2 Global Thrombopoiesis Stimulating Agents Growth Trends by Region
2.2.1 Global Thrombopoiesis Stimulating Agents Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Thrombopoiesis Stimulating Agents Historic Market Size by Region (2020-2025)
2.2.3 Thrombopoiesis Stimulating Agents Forecasted Market Size by Region (2026-2031)
2.3 Thrombopoiesis Stimulating Agents Market Dynamics
2.3.1 Thrombopoiesis Stimulating Agents Industry Trends
2.3.2 Thrombopoiesis Stimulating Agents Market Drivers
2.3.3 Thrombopoiesis Stimulating Agents Market Challenges
2.3.4 Thrombopoiesis Stimulating Agents Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Thrombopoiesis Stimulating Agents Players by Revenue
3.1.1 Global Top Thrombopoiesis Stimulating Agents Players by Revenue (2020-2025)
3.1.2 Global Thrombopoiesis Stimulating Agents Revenue Market Share by Players (2020-2025)
3.2 Global Thrombopoiesis Stimulating Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Thrombopoiesis Stimulating Agents Revenue
3.4 Global Thrombopoiesis Stimulating Agents Market Concentration Ratio
3.4.1 Global Thrombopoiesis Stimulating Agents Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Thrombopoiesis Stimulating Agents Revenue in 2024
3.5 Global Key Players of Thrombopoiesis Stimulating Agents Head office and Area Served
3.6 Global Key Players of Thrombopoiesis Stimulating Agents, Product and Application
3.7 Global Key Players of Thrombopoiesis Stimulating Agents, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Thrombopoiesis Stimulating Agents Breakdown Data by Type
4.1 Global Thrombopoiesis Stimulating Agents Historic Market Size by Type (2020-2025)
4.2 Global Thrombopoiesis Stimulating Agents Forecasted Market Size by Type (2026-2031)
5 Thrombopoiesis Stimulating Agents Breakdown Data by Application
5.1 Global Thrombopoiesis Stimulating Agents Historic Market Size by Application (2020-2025)
5.2 Global Thrombopoiesis Stimulating Agents Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Thrombopoiesis Stimulating Agents Market Size (2020-2031)
6.2 North America Thrombopoiesis Stimulating Agents Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025)
6.4 North America Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Thrombopoiesis Stimulating Agents Market Size (2020-2031)
7.2 Europe Thrombopoiesis Stimulating Agents Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025)
7.4 Europe Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Thrombopoiesis Stimulating Agents Market Size (2020-2031)
8.2 Asia-Pacific Thrombopoiesis Stimulating Agents Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Thrombopoiesis Stimulating Agents Market Size by Region (2020-2025)
8.4 Asia-Pacific Thrombopoiesis Stimulating Agents Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Thrombopoiesis Stimulating Agents Market Size (2020-2031)
9.2 Latin America Thrombopoiesis Stimulating Agents Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025)
9.4 Latin America Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Thrombopoiesis Stimulating Agents Market Size (2020-2031)
10.2 Middle East & Africa Thrombopoiesis Stimulating Agents Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025)
10.4 Middle East & Africa Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Thrombopoiesis Stimulating Agents Introduction
11.1.4 Amgen Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.1.5 Amgen Recent Development
11.2 Kyowa Kirin
11.2.1 Kyowa Kirin Company Details
11.2.2 Kyowa Kirin Business Overview
11.2.3 Kyowa Kirin Thrombopoiesis Stimulating Agents Introduction
11.2.4 Kyowa Kirin Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.2.5 Kyowa Kirin Recent Development
11.3 Intas Pharmaceuticals
11.3.1 Intas Pharmaceuticals Company Details
11.3.2 Intas Pharmaceuticals Business Overview
11.3.3 Intas Pharmaceuticals Thrombopoiesis Stimulating Agents Introduction
11.3.4 Intas Pharmaceuticals Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.3.5 Intas Pharmaceuticals Recent Development
11.4 SHIONOGI
11.4.1 SHIONOGI Company Details
11.4.2 SHIONOGI Business Overview
11.4.3 SHIONOGI Thrombopoiesis Stimulating Agents Introduction
11.4.4 SHIONOGI Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.4.5 SHIONOGI Recent Development
11.5 Novartis Pharma
11.5.1 Novartis Pharma Company Details
11.5.2 Novartis Pharma Business Overview
11.5.3 Novartis Pharma Thrombopoiesis Stimulating Agents Introduction
11.5.4 Novartis Pharma Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.5.5 Novartis Pharma Recent Development
11.6 AkaRx
11.6.1 AkaRx Company Details
11.6.2 AkaRx Business Overview
11.6.3 AkaRx Thrombopoiesis Stimulating Agents Introduction
11.6.4 AkaRx Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.6.5 AkaRx Recent Development
11.7 Rigel Pharmaceuticals
11.7.1 Rigel Pharmaceuticals Company Details
11.7.2 Rigel Pharmaceuticals Business Overview
11.7.3 Rigel Pharmaceuticals Thrombopoiesis Stimulating Agents Introduction
11.7.4 Rigel Pharmaceuticals Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.7.5 Rigel Pharmaceuticals Recent Development
11.8 Kissei Pharmaceutical
11.8.1 Kissei Pharmaceutical Company Details
11.8.2 Kissei Pharmaceutical Business Overview
11.8.3 Kissei Pharmaceutical Thrombopoiesis Stimulating Agents Introduction
11.8.4 Kissei Pharmaceutical Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.8.5 Kissei Pharmaceutical Recent Development
11.9 Grifols
11.9.1 Grifols Company Details
11.9.2 Grifols Business Overview
11.9.3 Grifols Thrombopoiesis Stimulating Agents Introduction
11.9.4 Grifols Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.9.5 Grifols Recent Development
11.10 JW Pharmaceutical Corporation
11.10.1 JW Pharmaceutical Corporation Company Details
11.10.2 JW Pharmaceutical Corporation Business Overview
11.10.3 JW Pharmaceutical Corporation Thrombopoiesis Stimulating Agents Introduction
11.10.4 JW Pharmaceutical Corporation Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.10.5 JW Pharmaceutical Corporation Recent Development
11.11 Medison Pharma Canada
11.11.1 Medison Pharma Canada Company Details
11.11.2 Medison Pharma Canada Business Overview
11.11.3 Medison Pharma Canada Thrombopoiesis Stimulating Agents Introduction
11.11.4 Medison Pharma Canada Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.11.5 Medison Pharma Canada Recent Development
11.12 AstraZeneca
11.12.1 AstraZeneca Company Details
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Thrombopoiesis Stimulating Agents Introduction
11.12.4 AstraZeneca Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025)
11.12.5 AstraZeneca Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Thrombopoiesis Stimulating Agents Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Romiplostim
Table 3. Key Players of Fostamatinib
Table 4. Key Players of Mulpleta
Table 5. Key Players of Doptelet
Table 6. Key Players of Others
Table 7. Global Thrombopoiesis Stimulating Agents Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Thrombopoiesis Stimulating Agents Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Thrombopoiesis Stimulating Agents Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Thrombopoiesis Stimulating Agents Market Share by Region (2020-2025)
Table 11. Global Thrombopoiesis Stimulating Agents Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Thrombopoiesis Stimulating Agents Market Share by Region (2026-2031)
Table 13. Thrombopoiesis Stimulating Agents Market Trends
Table 14. Thrombopoiesis Stimulating Agents Market Drivers
Table 15. Thrombopoiesis Stimulating Agents Market Challenges
Table 16. Thrombopoiesis Stimulating Agents Market Restraints
Table 17. Global Thrombopoiesis Stimulating Agents Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Thrombopoiesis Stimulating Agents Market Share by Players (2020-2025)
Table 19. Global Top Thrombopoiesis Stimulating Agents Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Thrombopoiesis Stimulating Agents as of 2024)
Table 20. Ranking of Global Top Thrombopoiesis Stimulating Agents Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Thrombopoiesis Stimulating Agents Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Thrombopoiesis Stimulating Agents, Headquarters and Area Served
Table 23. Global Key Players of Thrombopoiesis Stimulating Agents, Product and Application
Table 24. Global Key Players of Thrombopoiesis Stimulating Agents, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Thrombopoiesis Stimulating Agents Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Thrombopoiesis Stimulating Agents Revenue Market Share by Type (2020-2025)
Table 28. Global Thrombopoiesis Stimulating Agents Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Thrombopoiesis Stimulating Agents Revenue Market Share by Type (2026-2031)
Table 30. Global Thrombopoiesis Stimulating Agents Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Thrombopoiesis Stimulating Agents Revenue Market Share by Application (2020-2025)
Table 32. Global Thrombopoiesis Stimulating Agents Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Thrombopoiesis Stimulating Agents Revenue Market Share by Application (2026-2031)
Table 34. North America Thrombopoiesis Stimulating Agents Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Thrombopoiesis Stimulating Agents Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Thrombopoiesis Stimulating Agents Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Thrombopoiesis Stimulating Agents Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Thrombopoiesis Stimulating Agents Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Thrombopoiesis Stimulating Agents Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Thrombopoiesis Stimulating Agents Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031) & (US$ Million)
Table 49. Amgen Company Details
Table 50. Amgen Business Overview
Table 51. Amgen Thrombopoiesis Stimulating Agents Product
Table 52. Amgen Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 53. Amgen Recent Development
Table 54. Kyowa Kirin Company Details
Table 55. Kyowa Kirin Business Overview
Table 56. Kyowa Kirin Thrombopoiesis Stimulating Agents Product
Table 57. Kyowa Kirin Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 58. Kyowa Kirin Recent Development
Table 59. Intas Pharmaceuticals Company Details
Table 60. Intas Pharmaceuticals Business Overview
Table 61. Intas Pharmaceuticals Thrombopoiesis Stimulating Agents Product
Table 62. Intas Pharmaceuticals Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 63. Intas Pharmaceuticals Recent Development
Table 64. SHIONOGI Company Details
Table 65. SHIONOGI Business Overview
Table 66. SHIONOGI Thrombopoiesis Stimulating Agents Product
Table 67. SHIONOGI Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 68. SHIONOGI Recent Development
Table 69. Novartis Pharma Company Details
Table 70. Novartis Pharma Business Overview
Table 71. Novartis Pharma Thrombopoiesis Stimulating Agents Product
Table 72. Novartis Pharma Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 73. Novartis Pharma Recent Development
Table 74. AkaRx Company Details
Table 75. AkaRx Business Overview
Table 76. AkaRx Thrombopoiesis Stimulating Agents Product
Table 77. AkaRx Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 78. AkaRx Recent Development
Table 79. Rigel Pharmaceuticals Company Details
Table 80. Rigel Pharmaceuticals Business Overview
Table 81. Rigel Pharmaceuticals Thrombopoiesis Stimulating Agents Product
Table 82. Rigel Pharmaceuticals Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 83. Rigel Pharmaceuticals Recent Development
Table 84. Kissei Pharmaceutical Company Details
Table 85. Kissei Pharmaceutical Business Overview
Table 86. Kissei Pharmaceutical Thrombopoiesis Stimulating Agents Product
Table 87. Kissei Pharmaceutical Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 88. Kissei Pharmaceutical Recent Development
Table 89. Grifols Company Details
Table 90. Grifols Business Overview
Table 91. Grifols Thrombopoiesis Stimulating Agents Product
Table 92. Grifols Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 93. Grifols Recent Development
Table 94. JW Pharmaceutical Corporation Company Details
Table 95. JW Pharmaceutical Corporation Business Overview
Table 96. JW Pharmaceutical Corporation Thrombopoiesis Stimulating Agents Product
Table 97. JW Pharmaceutical Corporation Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 98. JW Pharmaceutical Corporation Recent Development
Table 99. Medison Pharma Canada Company Details
Table 100. Medison Pharma Canada Business Overview
Table 101. Medison Pharma Canada Thrombopoiesis Stimulating Agents Product
Table 102. Medison Pharma Canada Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 103. Medison Pharma Canada Recent Development
Table 104. AstraZeneca Company Details
Table 105. AstraZeneca Business Overview
Table 106. AstraZeneca Thrombopoiesis Stimulating Agents Product
Table 107. AstraZeneca Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 108. AstraZeneca Recent Development
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
Table 112. Authors List of This Report
List of Figures
Figure 1. Thrombopoiesis Stimulating Agents Picture
Figure 2. Global Thrombopoiesis Stimulating Agents Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Thrombopoiesis Stimulating Agents Market Share by Type: 2024 VS 2031
Figure 4. Romiplostim Features
Figure 5. Fostamatinib Features
Figure 6. Mulpleta Features
Figure 7. Doptelet Features
Figure 8. Others Features
Figure 9. Global Thrombopoiesis Stimulating Agents Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Thrombopoiesis Stimulating Agents Market Share by Application: 2024 VS 2031
Figure 11. Adults Case Studies
Figure 12. Pediatric Patients Case Studies
Figure 13. Thrombopoiesis Stimulating Agents Report Years Considered
Figure 14. Global Thrombopoiesis Stimulating Agents Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Thrombopoiesis Stimulating Agents Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Thrombopoiesis Stimulating Agents Market Share by Region: 2024 VS 2031
Figure 17. Global Thrombopoiesis Stimulating Agents Market Share by Players in 2024
Figure 18. Global Top Thrombopoiesis Stimulating Agents Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Thrombopoiesis Stimulating Agents as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Thrombopoiesis Stimulating Agents Revenue in 2024
Figure 20. North America Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Thrombopoiesis Stimulating Agents Market Share by Country (2020-2031)
Figure 22. United States Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Thrombopoiesis Stimulating Agents Market Share by Country (2020-2031)
Figure 26. Germany Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Thrombopoiesis Stimulating Agents Market Share by Region (2020-2031)
Figure 34. China Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Thrombopoiesis Stimulating Agents Market Share by Country (2020-2031)
Figure 42. Mexico Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Thrombopoiesis Stimulating Agents Market Share by Country (2020-2031)
Figure 46. Turkey Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Amgen Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 50. Kyowa Kirin Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 51. Intas Pharmaceuticals Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 52. SHIONOGI Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 53. Novartis Pharma Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 54. AkaRx Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 55. Rigel Pharmaceuticals Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 56. Kissei Pharmaceutical Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 57. Grifols Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 58. JW Pharmaceutical Corporation Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 59. Medison Pharma Canada Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 60. AstraZeneca Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Thrombopoiesis Stimulating Agents Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Romiplostim
Table 3. Key Players of Fostamatinib
Table 4. Key Players of Mulpleta
Table 5. Key Players of Doptelet
Table 6. Key Players of Others
Table 7. Global Thrombopoiesis Stimulating Agents Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Thrombopoiesis Stimulating Agents Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Thrombopoiesis Stimulating Agents Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Thrombopoiesis Stimulating Agents Market Share by Region (2020-2025)
Table 11. Global Thrombopoiesis Stimulating Agents Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Thrombopoiesis Stimulating Agents Market Share by Region (2026-2031)
Table 13. Thrombopoiesis Stimulating Agents Market Trends
Table 14. Thrombopoiesis Stimulating Agents Market Drivers
Table 15. Thrombopoiesis Stimulating Agents Market Challenges
Table 16. Thrombopoiesis Stimulating Agents Market Restraints
Table 17. Global Thrombopoiesis Stimulating Agents Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Thrombopoiesis Stimulating Agents Market Share by Players (2020-2025)
Table 19. Global Top Thrombopoiesis Stimulating Agents Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Thrombopoiesis Stimulating Agents as of 2024)
Table 20. Ranking of Global Top Thrombopoiesis Stimulating Agents Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Thrombopoiesis Stimulating Agents Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Thrombopoiesis Stimulating Agents, Headquarters and Area Served
Table 23. Global Key Players of Thrombopoiesis Stimulating Agents, Product and Application
Table 24. Global Key Players of Thrombopoiesis Stimulating Agents, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Thrombopoiesis Stimulating Agents Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Thrombopoiesis Stimulating Agents Revenue Market Share by Type (2020-2025)
Table 28. Global Thrombopoiesis Stimulating Agents Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Thrombopoiesis Stimulating Agents Revenue Market Share by Type (2026-2031)
Table 30. Global Thrombopoiesis Stimulating Agents Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Thrombopoiesis Stimulating Agents Revenue Market Share by Application (2020-2025)
Table 32. Global Thrombopoiesis Stimulating Agents Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Thrombopoiesis Stimulating Agents Revenue Market Share by Application (2026-2031)
Table 34. North America Thrombopoiesis Stimulating Agents Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Thrombopoiesis Stimulating Agents Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Thrombopoiesis Stimulating Agents Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Thrombopoiesis Stimulating Agents Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Thrombopoiesis Stimulating Agents Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Thrombopoiesis Stimulating Agents Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Thrombopoiesis Stimulating Agents Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Thrombopoiesis Stimulating Agents Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Thrombopoiesis Stimulating Agents Market Size by Country (2026-2031) & (US$ Million)
Table 49. Amgen Company Details
Table 50. Amgen Business Overview
Table 51. Amgen Thrombopoiesis Stimulating Agents Product
Table 52. Amgen Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 53. Amgen Recent Development
Table 54. Kyowa Kirin Company Details
Table 55. Kyowa Kirin Business Overview
Table 56. Kyowa Kirin Thrombopoiesis Stimulating Agents Product
Table 57. Kyowa Kirin Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 58. Kyowa Kirin Recent Development
Table 59. Intas Pharmaceuticals Company Details
Table 60. Intas Pharmaceuticals Business Overview
Table 61. Intas Pharmaceuticals Thrombopoiesis Stimulating Agents Product
Table 62. Intas Pharmaceuticals Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 63. Intas Pharmaceuticals Recent Development
Table 64. SHIONOGI Company Details
Table 65. SHIONOGI Business Overview
Table 66. SHIONOGI Thrombopoiesis Stimulating Agents Product
Table 67. SHIONOGI Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 68. SHIONOGI Recent Development
Table 69. Novartis Pharma Company Details
Table 70. Novartis Pharma Business Overview
Table 71. Novartis Pharma Thrombopoiesis Stimulating Agents Product
Table 72. Novartis Pharma Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 73. Novartis Pharma Recent Development
Table 74. AkaRx Company Details
Table 75. AkaRx Business Overview
Table 76. AkaRx Thrombopoiesis Stimulating Agents Product
Table 77. AkaRx Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 78. AkaRx Recent Development
Table 79. Rigel Pharmaceuticals Company Details
Table 80. Rigel Pharmaceuticals Business Overview
Table 81. Rigel Pharmaceuticals Thrombopoiesis Stimulating Agents Product
Table 82. Rigel Pharmaceuticals Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 83. Rigel Pharmaceuticals Recent Development
Table 84. Kissei Pharmaceutical Company Details
Table 85. Kissei Pharmaceutical Business Overview
Table 86. Kissei Pharmaceutical Thrombopoiesis Stimulating Agents Product
Table 87. Kissei Pharmaceutical Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 88. Kissei Pharmaceutical Recent Development
Table 89. Grifols Company Details
Table 90. Grifols Business Overview
Table 91. Grifols Thrombopoiesis Stimulating Agents Product
Table 92. Grifols Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 93. Grifols Recent Development
Table 94. JW Pharmaceutical Corporation Company Details
Table 95. JW Pharmaceutical Corporation Business Overview
Table 96. JW Pharmaceutical Corporation Thrombopoiesis Stimulating Agents Product
Table 97. JW Pharmaceutical Corporation Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 98. JW Pharmaceutical Corporation Recent Development
Table 99. Medison Pharma Canada Company Details
Table 100. Medison Pharma Canada Business Overview
Table 101. Medison Pharma Canada Thrombopoiesis Stimulating Agents Product
Table 102. Medison Pharma Canada Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 103. Medison Pharma Canada Recent Development
Table 104. AstraZeneca Company Details
Table 105. AstraZeneca Business Overview
Table 106. AstraZeneca Thrombopoiesis Stimulating Agents Product
Table 107. AstraZeneca Revenue in Thrombopoiesis Stimulating Agents Business (2020-2025) & (US$ Million)
Table 108. AstraZeneca Recent Development
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
Table 112. Authors List of This Report
List of Figures
Figure 1. Thrombopoiesis Stimulating Agents Picture
Figure 2. Global Thrombopoiesis Stimulating Agents Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Thrombopoiesis Stimulating Agents Market Share by Type: 2024 VS 2031
Figure 4. Romiplostim Features
Figure 5. Fostamatinib Features
Figure 6. Mulpleta Features
Figure 7. Doptelet Features
Figure 8. Others Features
Figure 9. Global Thrombopoiesis Stimulating Agents Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Thrombopoiesis Stimulating Agents Market Share by Application: 2024 VS 2031
Figure 11. Adults Case Studies
Figure 12. Pediatric Patients Case Studies
Figure 13. Thrombopoiesis Stimulating Agents Report Years Considered
Figure 14. Global Thrombopoiesis Stimulating Agents Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Thrombopoiesis Stimulating Agents Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Thrombopoiesis Stimulating Agents Market Share by Region: 2024 VS 2031
Figure 17. Global Thrombopoiesis Stimulating Agents Market Share by Players in 2024
Figure 18. Global Top Thrombopoiesis Stimulating Agents Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Thrombopoiesis Stimulating Agents as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Thrombopoiesis Stimulating Agents Revenue in 2024
Figure 20. North America Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Thrombopoiesis Stimulating Agents Market Share by Country (2020-2031)
Figure 22. United States Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Thrombopoiesis Stimulating Agents Market Share by Country (2020-2031)
Figure 26. Germany Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Thrombopoiesis Stimulating Agents Market Share by Region (2020-2031)
Figure 34. China Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Thrombopoiesis Stimulating Agents Market Share by Country (2020-2031)
Figure 42. Mexico Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Thrombopoiesis Stimulating Agents Market Share by Country (2020-2031)
Figure 46. Turkey Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Thrombopoiesis Stimulating Agents Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Amgen Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 50. Kyowa Kirin Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 51. Intas Pharmaceuticals Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 52. SHIONOGI Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 53. Novartis Pharma Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 54. AkaRx Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 55. Rigel Pharmaceuticals Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 56. Kissei Pharmaceutical Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 57. Grifols Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 58. JW Pharmaceutical Corporation Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 59. Medison Pharma Canada Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 60. AstraZeneca Revenue Growth Rate in Thrombopoiesis Stimulating Agents Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Allergen Detection Market Research Report 2025
Jun 28, 25
Global Electronic Health Tracking System Market Research Report 2025
Jun 28, 25
Global Speciality Optical Fibers Market Research Report 2025
Jun 28, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232